Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy
OBJECTIVES: Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in patients under mono or dual therapy.
METHODS: This was a prospective multicenter cohort study of patients using DRV/r under mono or dual therapy plus lamivudine who changed to DRV/c maintaining the previous regimen. All patients had a controlled HIV viral load (<50 copies/ml) when switched and were examined every 12 weeks. The primary end-point was the percentage of participants without virological failure (VF) at week 48 in the intent-to-treat analysis. The CD4 cell count and concentrations of cholesterol, triglyceride, and creatinine were measured from baseline to week 48.
RESULTS: A total of 162 patients were included: 68.5% were men, and their mean age was 46 ± 12 years. Seventy (43.2%) patients were treated with DRV/r monotherapy, and 92 (56.8%) were treated with DRV/r plus lamivudine. The efficacy at week 48 was 95.1% (95% CI: 90.6%-97.5%) in the intent-to-treat analysis and 98.7% (95.5-99.6%) in the on-treatment analysis. Two VFs were documented but without development of resistance mutations. No significant changes were found in the lipid profile. Creatinine concentration increased significantly by 0.07 mg/dl (0.04-0.10, P < 0.001).
CONCLUSIONS: Switching from DRV/r to DRV/c in patients under mono or dual therapy is safe and effective.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
HIV clinical trials - 19(2018), 5 vom: 04. Okt., Seite 197-201 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mena, Álvaro [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.04.2019 Date Revised 30.04.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/15284336.2018.1513974 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM292336985 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM292336985 | ||
| 003 | DE-627 | ||
| 005 | 20231225072855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15284336.2018.1513974 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0974.xml |
| 035 | |a (DE-627)NLM292336985 | ||
| 035 | |a (NLM)30605006 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mena, Álvaro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.04.2019 | ||
| 500 | |a Date Revised 30.04.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in patients under mono or dual therapy | ||
| 520 | |a METHODS: This was a prospective multicenter cohort study of patients using DRV/r under mono or dual therapy plus lamivudine who changed to DRV/c maintaining the previous regimen. All patients had a controlled HIV viral load (<50 copies/ml) when switched and were examined every 12 weeks. The primary end-point was the percentage of participants without virological failure (VF) at week 48 in the intent-to-treat analysis. The CD4 cell count and concentrations of cholesterol, triglyceride, and creatinine were measured from baseline to week 48 | ||
| 520 | |a RESULTS: A total of 162 patients were included: 68.5% were men, and their mean age was 46 ± 12 years. Seventy (43.2%) patients were treated with DRV/r monotherapy, and 92 (56.8%) were treated with DRV/r plus lamivudine. The efficacy at week 48 was 95.1% (95% CI: 90.6%-97.5%) in the intent-to-treat analysis and 98.7% (95.5-99.6%) in the on-treatment analysis. Two VFs were documented but without development of resistance mutations. No significant changes were found in the lipid profile. Creatinine concentration increased significantly by 0.07 mg/dl (0.04-0.10, P < 0.001) | ||
| 520 | |a CONCLUSIONS: Switching from DRV/r to DRV/c in patients under mono or dual therapy is safe and effective | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Darunavir/cobicistat | |
| 650 | 4 | |a dual therapy | |
| 650 | 4 | |a monotherapy | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 7 | |a Cobicistat |2 NLM | |
| 650 | 7 | |a LW2E03M5PG |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Darunavir |2 NLM | |
| 650 | 7 | |a YO603Y8113 |2 NLM | |
| 700 | 1 | |a Cid, Purificación |e verfasserin |4 aut | |
| 700 | 1 | |a Dueñas, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Garcinuño, María Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Juan Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Margusino, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Quiñones, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Grande, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Osorio, Iria |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Ángeles |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HIV clinical trials |d 2000 |g 19(2018), 5 vom: 04. Okt., Seite 197-201 |w (DE-627)NLM114850178 |x 1528-4336 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:5 |g day:04 |g month:10 |g pages:197-201 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15284336.2018.1513974 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2018 |e 5 |b 04 |c 10 |h 197-201 | ||